ABP AMERICANBIOETHICS PROJECT

In the early 1970s, recombinant DNA techniques made it possible to combine genetic material in new ways.

The possibilities generated scientific excitement and concern. Researchers themselves worried that experiments might create biological hazards that were poorly understood.

The Asilomar Conference on Recombinant DNA in 1975 became an important episode in the history of scientific self-governance. Scientists developed containment practices intended to permit research while reducing uncertain risks.

Asilomar demonstrated that scientific progress and restraint need not be opposites.

It also left a larger question unresolved.

Who should govern science when the consequences of scientific decisions extend beyond the scientists performing the work?

Expertise is indispensable for understanding the technology. Expertise alone cannot determine what society should value.

The Human Genome Project, formally launched in 1990, transformed genetics into a large-scale international scientific enterprise.

The project sought to map and sequence the human genome. It also devoted resources to the ethical, legal, and social implications of genomic research through what became known as the ELSI program.

That decision reflected an important recognition: obtaining genetic knowledge and determining how that knowledge should be used were different tasks.

Genomic information raised questions about privacy, insurance, employment, familial disclosure, population classification, and the right not to know.

Genetic testing could also produce an unusual form of medical knowledge: information about serious future risk for which medicine had little or no effective treatment.

Knowledge could therefore increase without increasing control.

Genetic technologies gradually moved from identifying disease toward shaping reproductive decisions.

Carrier screening could identify reproductive risk before conception. Prenatal diagnosis could detect some conditions during pregnancy. IVF combined with preimplantation genetic testing made it possible to obtain genetic information about embryos before deciding which embryo to transfer.

These technologies can be used to avoid devastating childhood diseases.

But they also make a new kind of decision possible.

Medicine no longer asks only, How should we treat the patient who exists?

It can also ask, Which possible future child should come to exist?

That distinction is ethically significant.

The ability to select does not tell us what should be selected.

Genetic medicine developed in a country with its own history of eugenics.

American eugenic programs had also appealed to heredity, biological knowledge, disease prevention, and improvement of future generations. Their consequences included compulsory sterilization and classifications shaped by disability, race, poverty, immigration, and judgments of social worth.

Contemporary genomics is not simply another name for eugenics.

The science is different. The institutions are different. Individual choice often plays a much larger role. Many genetic interventions seek to relieve serious suffering rather than pursue state-directed population improvement.

Yet the history remains relevant because biotechnology repeatedly requires someone to identify a desirable outcome.

Who defines disease? Who defines improvement? And who bears the consequences when those definitions are mistaken?

Genetic knowledge naturally generated hopes that disease-causing genes might not merely be identified but treated.

Early gene-therapy experiments attempted to introduce genetic material into patients to correct or compensate for disease.

In 1999, Jesse Gelsinger, an eighteen-year-old participant in a gene-therapy trial, died following an experimental intervention. His death prompted intense scrutiny of research oversight, informed consent, adverse-event reporting, conflicts of interest, and the relationship between scientific enthusiasm and participant protection.

The episode connected biotechnology back to one of bioethics' oldest lessons.

A promising future benefit does not eliminate obligations to the person presently exposed to risk.

The announcement of Dolly the sheep, the first mammal cloned from an adult somatic cell, transformed public discussion of cloning.

A technique demonstrated in an animal made human reproductive cloning imaginable in a new way.

At roughly the same time, embryonic stem-cell research intensified longstanding disagreements over the moral status of human embryos.

Researchers emphasized the scientific and potential therapeutic importance of pluripotent cells. Opponents argued that valuable scientific ends could not justify the destruction of embryonic human life. Other positions attributed embryos significant but not equivalent moral status to born persons.

The dispute returned bioethics to a recurring problem:

Can something possess serious moral significance without possessing full personhood—and, if so, what follows from that status?

The development of CRISPR-Cas9 made targeted genome editing dramatically more accessible and efficient.

A crucial distinction emerged between somatic interventions and germline interventions.

Somatic editing affects cells in an existing patient and ordinarily ends with that patient. Germline modification can alter embryos, eggs, or sperm in ways capable of being inherited by future generations.

In 2018, Chinese scientist He Jiankui announced the births of children whose embryos he had genetically edited.

The international scientific response was overwhelmingly critical.

But the episode established something historically important: heritable human genome editing was no longer merely speculative.

Future generations could now become subjects of decisions made before their existence.

Bioethics often distinguishes therapy from enhancement.

Therapy seeks to restore or preserve health. Enhancement attempts to move a person beyond what is considered normal functioning.

The distinction has intuitive appeal.

It is also unstable.

What counts as normal? Hearing interventions may be understood as treatment within medicine and as a challenge to cultural identity within some Deaf communities. Growth-related interventions can treat recognized pathology or alter stature at the margins of ordinary variation. Genetic interventions that begin with severe disease may eventually be considered for traits associated with performance or appearance.

The therapy-enhancement distinction helps organize the debate.

It does not settle it.

From recombinant DNA to CRISPR, biotechnology repeatedly returns bioethics to the problem of governance.

Scientists possess specialized knowledge. Patients and families live with disease. Disabled communities may understand conditions differently from researchers seeking to prevent them. Governments regulate risk. Companies possess capital and intellectual property. Religious and philosophical traditions provide competing accounts of human flourishing and moral limits.

No single group possesses an uncontested claim to decide alone.

The problem becomes especially difficult when decisions affect people who cannot participate because they do not yet exist.

Future generations cannot consent to inherited genetic alterations.

But refusing intervention can also shape their lives.

Nonintervention is not always morally neutral simply because it preserves what would otherwise occur naturally.

Biotechnology made human biological possibility itself increasingly available for deliberate choice.

Genetics expanded bioethical attention beyond the individual patient. Information can implicate relatives. Reproductive decisions can affect future children. Germline interventions can reach descendants. Population genetics can shape how societies understand human difference.

The central question is therefore larger than whether biotechnology is good or dangerous.

It concerns which interventions constitute responsible care, which express contestable visions of human improvement, who bears their risks, and who has authority to make choices whose consequences may extend beyond the people making them.

1. 1973

   Recombinant DNA techniques emerge

2. 1975

   Asilomar Conference

3. 1990

   Human Genome Project begins

4. 1990

   Early human gene-therapy trial

5. 1996–1997

   Dolly the sheep

6. 1999

   Jesse Gelsinger dies during a gene-therapy trial

7. 2003

   Human Genome Project completed

8. 2012

   CRISPR-Cas9 emerges as a transformative genome-editing technology

9. 2018

   Birth of genome-edited children announced